Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population

BACKGROUND: The purpose of this study was to estimate the annual cost per treated patient for the tumor necrosis factor (TNF) blockers, etanercept, adalimumab, and infliximab in rheumatoid arthritis (RA) patients covered by Medicaid. METHODS: The MarketScan Medicaid Multistate Database was used to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonafede, Machaon, Joseph, George J, Shah, Neel, Princic, Nicole, Harrison, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168856/
https://www.ncbi.nlm.nih.gov/pubmed/25246804
http://dx.doi.org/10.2147/CEOR.S61445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168856/
https://www.ncbi.nlm.nih.gov/pubmed/25246804
http://dx.doi.org/10.2147/CEOR.S61445

Ejemplares similares